Kalaris Therapeutics (KLRS) Earnings Date & Reports

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

KLRS is expected to report earnings to rise 8.85% to -52 cents per share on November 18

Kalaris Therapeutics KLRS Stock Earnings Reports

Q3'26

Est.

$-0.52

Q2'26

Beat

by $0.02

Q1'26

Beat

by $0.10

Q4'25

Missed

by $0.34

The last earnings report on August 11 showed earnings per share of -47 cents, beating the estimate of -50 cents. With 147.45K shares outstanding, the current market capitalization sits at 67.73M.

View a ticker or compare two or three

KLRS

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for KLRS